• 2EyesVision was voted Most Innovative Company in the “Simultaneous Vision IOLs” category at ESCRS iNovation Day, receiving 43% of the votes.
• The 4th SimVis Gekko Users Meeting brought together clinicians and SimVis users under the theme “Mastering Clinical Decisions with Visual Simulation.”
• Two oral presentations and a presented poster added new evidence on how SimVis Gekko supports clinical decision-making, patient satisfaction and outcome prediction.

London, UK — 2EyesVision, an innovative ophthalmic technology company, was voted Most Innovative Company in the “Simultaneous Vision IOLs” category at ESCRS iNovation Day, receiving 43% of the votes. The recognition marked the start of an intense week for the company at the ESCRS 2026 Congress in London, where visual simulation confirmed its growing role in everyday clinical practice.

Most Innovative Company at ESCRS iNovation Day

Máximo Gómez, Chief Executive Officer of 2EyesVision, took the stage in the “Managing Presbyopia: Simultaneous Vision IOLs” session to present the company and SimVis Gekko to an audience focused on the technologies and ideas shaping the future of ophthalmology. The audience voted 2EyesVision as the most innovative company in the category.

This recognition comes as visual simulation is becoming part of clinical practice internationally, supported by growing scientific evidence and real-world experience. By bringing the patient’s visual experience into the preoperative process, SimVis Gekko is helping move the conversation around advanced IOLs towards greater personalization, better expectation management and more patient-centered care.

“This recognition comes at a time when visual simulation is already becoming part of clinical practice internationally. The question is no longer whether patients can experience their vision before surgery, but how far visual simulation can take us in personalizing the surgical journey.”

Máximo Gómez, Chief Executive Officer of 2EyesVision

4th SimVis Gekko Users Meeting

2EyesVision opened its ESCRS agenda with the 4th SimVis Gekko Users Meeting, under the theme “Mastering Clinical Decisions with Visual Simulation.” The meeting set out to answer one question: how can real-world visual simulation lead to better real-world outcomes? Clinicians and SimVis users came together to share how visual simulation is being integrated into everyday practice, from patient counselling and clinical grey zones to expectation management, patient profiling and advanced-IOL decision-making.

The programme brought together different clinical perspectives:

• Patient experience and preoperative counselling, with Brendan Cummings.
• The latest developments from 2EyesVision, with Carlos Dorronsoro, Chief Innovation Officer, Founder & President of 2EyesVision.
• Real-world vs virtual reality simulation and a US perspective on preoperative counselling, with Dr. Scott MacRae.
• Using SimVis in clinical grey zones, with Dr. Nicolás Alejandre Alba.
• Improving patient satisfaction with SimVis, with Dr. Alicia Sánchez García.
• Psychological red flags between desire and reality in surgical practice, with Camille Bosc and Anaïs Nicolas.

The morning culminated in the expert panel “Managing the Modern Cataract Patient,” which brought together experienced SimVis users with the special participation of Dr. Erik Mertens, followed by Q&A, networking and live SimVis demonstrations. The goal was simple but ambitious: better patient conversations, more confident clinical decisions and stronger real-world outcomes.

New evidence on visual simulation

Two oral presentations and a presented poster at ESCRS 2026 added new evidence on the clinical role of preoperative visual simulation in cataract and refractive lens surgery.

The clinician perspective. In a multicentre survey, all clinicians reported greater confidence in their IOL recommendations after using SimVis, and the initial surgical plan was frequently modified after simulation. “Impact of Preoperative Visual Simulation on Clinical Decision-Making and Patient Counselling: A Multicentre Real-World Clinician Survey.” Presenter: Dr. Julien Combes.

The patient perspective. Preoperative simulation was associated with significantly less functional limitation from halos after surgery (4.8% vs 16.3%, p=0.002). Patients also rated the simulation as easy to understand and faithful to their actual postoperative vision. “Functional Outcomes After Visual Simulation in Refractive Cataract Surgery: A Patient-Reported Analysis.” Presenter: Dr. Alicia Sánchez García.

Predicting outcomes. In cataract patients, a calibrated model using preoperative SimVis measurements showed good ability to predict postoperative visual acuity, with results within ±2 lines in 100% of patients at far, 95% at intermediate and 82% at near. The same study showed that postoperative satisfaction cannot be explained by visual acuity alone: expectations and subjective visual experience matter. Preoperative preference measured with SimVis can help flag patients more vulnerable to dissatisfaction, who may benefit from closer expectation management before surgery. “Predicting Postoperative Visual Acuity with Different Intraocular Lenses Using Preoperative Visual Simulations in Patients with Cataracts.” Presenter: Dr. Sofía Bielsa.

Together, these findings point in the same direction: visual simulation is moving beyond showing patients what they may see. It is becoming a tool to support more personalized IOL recommendations, better expectation management and more informed conversations before surgery.

SimVis Gekko live at ESCRS 2026

Throughout the congress, visitors experienced SimVis Gekko first-hand at the 2EyesVision booth (C.332), trying different visual corrections while looking at the real world around them: checking their phones, looking across the hall, recognizing faces and exploring vision at different distances. No virtual environment. Real-world, binocular vision.

SimVis Gekko was also available at the Alcon booth (C.231), where attendees explored visual corrections from the Alcon IOL portfolio live.

Thank you to all our speakers, attendees and everyone who voted for 2EyesVision for sharing their experience, questions and perspectives, and to ESCRS iNovation for this recognition. A great week with the growing SimVis clinical community.

Want to know more about 2EyesVision at ESCRS 2026?

Visit our ESCRS 2026 page, contact the 2EyesVision team to book a SimVis Gekko demo, or read more company news in the 2EyesVision press room.

• CCOS 2026 took place from September 9 to 12 at the Tianjin Meijiang International Convention and Exhibition Center in Tianjin, China.
• The presence at CCOS follows 2EyesVision’s exclusive distribution agreement with Guangzhou DMK Technology for mainland China, Hong Kong and Macao.

Tianjin, China — 2EyesVision, an innovative ophthalmic technology company, presented SimVis Gekko at CCOS 2026, China’s most important ophthalmology congress, held from September 9 to 12 at the Tianjin Meijiang International Convention and Exhibition Center. While the international ophthalmology community gathered at major meetings that same week, SimVis Gekko was reaching clinicians in one of the world’s largest ophthalmic markets.

Hands-on with SimVis Gekko in China

At the booth of Guangzhou DMK Technology, Chinese ophthalmology professionals got hands-on with SimVis Gekko and experienced a different approach to preoperative counselling and IOL simulation.

Together with DMK, 2EyesVision introduced clinicians to what makes SimVis Gekko different: real-world visual simulation. Patients can experience the vision provided by different IOL corrections while looking at their actual surroundings. No virtual reality. Real vision, before surgery.

A milestone in 2EyesVision’s international expansion

The presence at CCOS is particularly significant following 2EyesVision’s exclusive distribution agreement with Guangzhou DMK Technology for mainland China, Hong Kong and Macao, an important milestone in the company’s international expansion, announced alongside the appointment of Máximo Gómez as Chief Executive Officer.

“China is one of the most important ophthalmic markets in the world, and CCOS has shown the strong interest of Chinese clinicians in real-world visual simulation. Together with DMK, we are bringing SimVis Gekko closer to ophthalmologists who want to offer their patients a more personalized and patient-centered surgical journey.”

Máximo Gómez, Chief Executive Officer of 2EyesVision

2EyesVision would like to thank Bao Yin and the entire DMK team for their work at CCOS and for bringing SimVis Gekko closer to the Chinese ophthalmology community.

From Tianjin to London

The same week, 2EyesVision was voted Most Innovative Company at ESCRS iNovation Day and held its 4th SimVis Gekko Users Meeting in London. Visual simulation is gaining momentum worldwide, with more clinicians exploring how it can support more personalized IOL recommendations, better-informed patients and a truly patient-centered approach to cataract and refractive surgery.

Want to know more?

Read about 2EyesVision at ESCRS 2026 and the company’s new leadership and distribution agreement in China, contact the 2EyesVision team or read more company news in the 2EyesVision press room.

• Carlos Dorronsoro, founder of 2EyesVision and CEO until now, will take on the role of Chief Innovation Officer, Founder & President, leading innovation, research and product development.
• 2EyesVision continues to drive its international expansion, having signed an exclusive distribution agreement for mainland China, Hong Kong and Macau, while advancing new opportunities in India and strengthening its presence in the United States.

Madrid, Spain — 2EyesVision, an innovative ophthalmic technology company backed by Bullnet Capital, has appointed Máximo Gómez as its new Chief Executive Officer (CEO) to lead the company’s next phase of growth and international expansion. At the same time, Carlos Dorronsoro, the company’s founder, will take on the role of Chief Innovation Officer, Founder & President, from which he will focus on innovation, research and product development.

Both appointments reflect the company’s evolution towards a more mature organisation with a reinforced management structure and complementary responsibilities. This new structure provides continuity and stability for the project and will strengthen the company’s ability to meet its upcoming challenges in growth, business development, international expansion and innovation, with both leaders’ renewed commitment to the future of 2EyesVision.

Máximo Gómez, Chief Executive Officer

Máximo Gómez takes on executive leadership of the company after joining 2EyesVision in 2025 with the goal of driving its strategy for growth, business development and international expansion. He brings nearly three decades of international experience in the healthcare sector, built at organisations including MSD, Abbott and Johnson & Johnson, where he held the position of General Manager and was a member of the European Committee of Johnson & Johnson Vision. His experience in implementing growth strategies and managing international businesses will be key to driving 2EyesVision’s expansion and accelerating the adoption of its technology in new markets.

“2EyesVision has a truly differentiated technology with enormous growth potential. Our goal is to keep consolidating the company’s development, strengthening our presence in the markets where we already operate and accelerating international expansion so that more and more professionals can bring our solutions into their clinical practice.”

Máximo Gómez, Chief Executive Officer of 2EyesVision

Carlos Dorronsoro, Chief Innovation Officer, Founder & President

For his part, Carlos Dorronsoro will focus his work on innovation, research, technology and product development. Co-founder of 2EyesVision alongside Susana Marcos, Dorronsoro holds a PhD in Visual Optics and is a Scientific Researcher at the CSIC. As the inventor of SimVis technology, he has led the development of SimVis Gekko, the visual simulator that allows patients to try out different intraocular lenses before cataract and presbyopia surgery.

SimVis Gekko is a binocular visual simulator that lets patients experience, before surgery, what their vision will be like with the different correction options for presbyopia and cataracts. This helps patients better understand each option and set realistic expectations, while giving ophthalmologists more information to guide the clinical decision, in two of the most common procedures worldwide.

“Since founding 2EyesVision, we have worked to develop a technology capable of transforming the way ophthalmologists and patients prepare for cataract or presbyopia surgery: patients understand their options better, and ophthalmologists decide with more information. This new stage will allow us to focus on continuing to drive innovation and develop new solutions that keep improving clinical practice and the patient experience.”

Carlos Dorronsoro, Chief Innovation Officer, Founder & President of 2EyesVision

Reflecting this new stage of growth, 2EyesVision has also moved its headquarters to new offices in Plaza de Castilla (Madrid). The new premises, larger and more centrally located, will allow the company to grow its team and continue strengthening its operational capacity. Contact the 2EyesVision team.

International expansion

The company continues to accelerate its international expansion. 2EyesVision has recently signed an exclusive distribution agreement with Guangzhou DMK Technology for mainland China, Hong Kong and Macau, strengthening its presence in one of the world’s largest ophthalmic markets. The company is also in talks to advance its entry into India and continues to strengthen its position in the United States, where it has been operating for several years. Read more company news in the 2EyesVision press room.

About Bullnet Capital

Bullnet Capital is an independent Spanish venture capital firm focused on high-technology companies (software, electronics, semiconductors, photonics). Established in 2002, it manages a total of €140 million across several investment vehicles. To date, Bullnet Capital has invested in thirty early-stage Spanish companies and maintains its investment philosophy of adding value and contributing to the day-to-day running of its portfolio companies.

www.bullnetcapital.com | @bullnetcapital

For further information

KREAB
José Luis González: jlgonzalez@kreab.com / 661 85 03 84
Olatz Ocáriz: oocariz@kreab.com / 692 59 31 85

• The event, powered by LaunchLab Partners and iDSocial, will take place on October 8, 2026, at Grand Oaks Mansion at Mardi Gras World, New Orleans.
• Attendees will be able to experience first-hand how different advanced presbyopic corrections perform in real-world conditions, before they are implanted in patients.

New Orleans, USA — 2EyesVision, an innovative ophthalmic technology company, has been selected as a Showcase Innovator at Innovators Pop Up 2026, powered by LaunchLab Partners and iDSocial. The event will take place on October 8, 2026, in New Orleans, just ahead of the American Academy of Ophthalmology (AAO) Annual Meeting.

Innovators Pop Up brings together ophthalmologists, industry leaders and emerging companies to discover the technologies shaping the future of eye care. At this year’s edition, 2EyesVision will offer attendees something that goes beyond a presentation: a live, first-hand experience of visual simulation.

Experience it, don’t just hear about it

With SimVis Gekko, eye care professionals can experience how different advanced presbyopic corrections perform in the real world, before they are implanted in patients. Unlike virtual reality-based solutions, SimVis Gekko delivers real, binocular, see-through vision. Users look at their actual surroundings — near, intermediate and far — through simulated corrections, gaining a realistic understanding of the visual performance each option offers. This approach supports a more personalized, patient-centered approach to cataract and refractive surgery: patients can better understand their options and set realistic expectations, while surgeons gain additional information to guide the clinical decision.

“Visual simulation is something you have to experience to fully understand. Innovators Pop Up is the ideal setting for ophthalmologists to see for themselves how SimVis Gekko can help them and their patients make more confident decisions before surgery.”

Máximo Gómez, Chief Executive Officer of 2EyesVision

Event details

Event: Innovators Pop Up 2026
Date: October 8, 2026
Time: 6:00–9:00 PM
Venue: Grand Oaks Mansion at Mardi Gras World, New Orleans

Professionals attending AAO in New Orleans are invited to meet Nivine B. Woods and the 2EyesVision team and experience visual simulation for themselves.

Register for Innovators Pop Up 2026

Seeing is believing. See you in New Orleans.

Want to learn more before the event?

Contact the 2EyesVision team or read more company news in the 2EyesVision press room.

Guangzhou, China — 2EyesVision, the company behind SimVis Gekko, the world’s first real-world visual simulator for cataract and presbyopia procedures, has signed an exclusive distribution agreement with Guangzhou DMK Technology Co., Ltd. for Mainland China, Hong Kong and Macao. The agreement marks a significant commercial milestone for 2EyesVision and reinforces the company’s international expansion strategy in one of the most dynamic ophthalmology markets worldwide.

Through this partnership, ophthalmologists across Greater China will gain access to SimVis Gekko, the visual simulator that allows patients to experience their future vision before surgery by viewing the real world through simulated intraocular lens corrections. The growing adoption of premium intraocular lenses has increased the need for tools that help patients better understand expected visual outcomes before surgery. By allowing patients to experience different visual corrections in real-world conditions, SimVis Gekko helps improve patient understanding, increase confidence during the consultation process, and support a more personalized recommendation process. The agreement was formally signed in China by representatives of both companies, including Máximo Gómez, Chief Strategy Officer at 2EyesVision, and Marica D’Angelo, International Markets Manager.

“China is one of the most important ophthalmology markets globally and a strategic region for the future growth of 2EyesVision. We are delighted to partner with DMK Technology to bring real-world visual simulation to surgeons and patients across Greater China. As premium cataract procedures continue to expand worldwide, visual simulation is becoming an increasingly valuable tool to improve patient understanding, support clinical conversations, and facilitate the adoption of advanced vision correction solutions,” said Máximo Gómez, Chief Strategy Officer at 2EyesVision.

“We are pleased to partner with 2EyesVision to bring SimVis Gekko to ophthalmologists across Greater China. We believe this innovative technology can help enhance patient understanding before surgery and support a more personalized consultation process. We look forward to introducing real-world visual simulation to eye care professionals throughout the region,” said Bao Yin, President of DMK Technology.

Founded in 1997, DMK Technology specializes in ophthalmic technologies and has extensive experience introducing innovative international solutions into the Chinese market.

The partnership represents another step toward 2EyesVision’s vision of making real-world visual simulation a standard part of the patient journey before cataract and refractive procedures worldwide.